Crown Bioscience Inc.
CrownBio Enhances Its European Capabilities with New Generation of Innovative Translational Models for Obesity and Diabetes
SANTA CLARA, Calif., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the availability of their proprietary FATZO(TM) model in a European based laboratory. The establishment of this improved translational model provides the European scientific community with unfettered access to an advanced research tool for use in preclinical studies of obesity, dysmetabolism and type 2 diabetes.
The FATZO(TM) is a next generation preclinical research model for obesity, metabolic disorders, diabetes and related complications. The unique feature of an intact leptin system enables the FATZO model to provide novel scientific insights into the physiological and cellular mechanisms that lead from obesity / metabolic disorders to diabetes. It examines polygenic causes of obesity and mimics human pathophysiology by exhibiting metabolic patterns of hyperglycemia and hyperinsulinemia.
"Obesity and diabetes have a significant global impact, affecting more than 422 million people worldwide. We expanded our FATZO(TM) model to ensure European researchers have ready access to the best translational tools available to advance the drug development programs aimed at curing these diseases," said Jim Wang, M.D., Crown Bioscience's Senior Vice President Cardiovascular and Metabolic Diseases (CVMD) Research.
"The establishment of our FATZO(TM) model in Europe is pivotal to Crown Bioscience's commitment to providing translational models that are representative of human conditions of obesity, type 2 diabetes and related comorbidities," said Jean-Pierre Wery, Ph.D., CEO of Crown Bioscience. "We look forward to working with European scientists to help answer their most challenging questions about these diseases and enable more effective drug discovery for their treatment."
For more information on CrownBio's commitment to advance the field of cardiovascular and metabolic drug discovery, visit https://www.crownbio.com/cvmd .
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Crown Bioscience Inc. email@example.com
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Percona13.12.2017 09:04 | pressemeddelelse
Percona Collaborates with AWS on Database Delivery Service
Upstream Security13.12.2017 09:03 | pressemeddelelse
Upstream Security Revs Up Cloud-Based Cybersecurity for Connected and Autonomous Car Fleets with $9M Series A
Percona13.12.2017 09:01 | pressemeddelelse
Percona Monitoring and Management 1.5 Provides Enhanced Cloud Support, Improved Interface
AMMO, Inc.12.12.2017 15:01 | pressemeddelelse
Ammo Incorporated Releases STREAK Visual Ammunition
Z-Wave Alliance12.12.2017 15:01 | pressemeddelelse
Global Smart Lock Leader ASSA ABLOY joins Z-Wave Alliance Board of Directors
Neato Robotics12.12.2017 15:01 | pressemeddelelse
Neato Appoints New CEO Matt Petersen
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum